Compare Stocks: ERAS, RVMD, GMAB, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$16.19	$18.35	$1.47 ▼ $24.28	$5.66B	0.64	3.53 million shs	2.06 million shs
GMAB Genmab A/S	$33.60	$30.47	$23.62 ▼ $35.43	$20.96B	0.84	2.63 million shs	1.00 million shs
RVMD Revolution Medicines	$210.02	$196.93	$39.17 ▼ $224.31	$45.02B	1.4	1.76 million shs	884,506 shs
UTHR United Therapeutics	$487.61	$525.95	$375.61 ▼ $609.35	$20.91B	0.56	481,822 shs	326,991 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	0.00%	-10.21%	-12.06%	+25.80%	+905.59%
GMAB Genmab A/S	0.00%	+1.11%	+7.52%	+35.48%	+22.00%
RVMD Revolution Medicines	0.00%	+1.03%	+2.37%	+41.44%	+418.57%
UTHR United Therapeutics	0.00%	-5.40%	-9.51%	-10.48%	+21.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$16.19	$18.35	$1.47 ▼ $24.28	$5.66B	0.64	3.53 million shs	2.06 million shs
GMAB Genmab A/S	$33.60	$30.47	$23.62 ▼ $35.43	$20.96B	0.84	2.63 million shs	1.00 million shs
RVMD Revolution Medicines	$210.02	$196.93	$39.17 ▼ $224.31	$45.02B	1.4	1.76 million shs	884,506 shs
UTHR United Therapeutics	$487.61	$525.95	$375.61 ▼ $609.35	$20.91B	0.56	481,822 shs	326,991 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	0.00%	-10.21%	-12.06%	+25.80%	+905.59%
GMAB Genmab A/S	0.00%	+1.11%	+7.52%	+35.48%	+22.00%
RVMD Revolution Medicines	0.00%	+1.03%	+2.37%	+41.44%	+418.57%
UTHR United Therapeutics	0.00%	-5.40%	-9.51%	-10.48%	+21.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	2.64	Moderate Buy	$22.09	36.45% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	17.56% Upside
RVMD Revolution Medicines	2.95	Moderate Buy	$200.74	-4.42% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	32.48% Upside

Current Analyst Ratings Breakdown

Latest ERAS, RVMD, GMAB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/31/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$240.00 ➝ $275.00
8/28/2026	RVMD Revolution Medicines	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$220.00 ➝ $265.00
8/28/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$240.00 ➝ $275.00
8/27/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/27/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$203.00 ➝ $251.00
8/27/2026	RVMD Revolution Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$248.00
8/27/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$230.00 ➝ $260.00
8/27/2026	RVMD Revolution Medicines	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$320.00
8/27/2026	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$195.00 ➝ $280.00
8/27/2026	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$201.00 ➝ $225.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
GMAB Genmab A/S	$3.72B	5.63	$1.61 per share	20.87	$9.10 per share	3.69
RVMD Revolution Medicines	$11.58M	3,887.37	N/A	N/A	$8.44 per share	24.88
UTHR United Therapeutics	$3.18B	6.57	$32.99 per share	14.78	$164.81 per share	2.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	26.46	20.74	1.99	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.45	16.43	2.43	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest ERAS, RVMD, GMAB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	8.29	8.29
GMAB Genmab A/S	0.81	2.46	2.44
RVMD Revolution Medicines	0.40	11.38	11.38
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
GMAB Genmab A/S	7.07%
RVMD Revolution Medicines	94.34%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.20%
GMAB Genmab A/S	1.54%
RVMD Revolution Medicines	7.60%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	349.76 million	300.10 million	Optionable
GMAB Genmab A/S	3,029	623.78 million	614.17 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

ERAS, RVMD, GMAB, and UTHR Headlines

Recent News About These Companies

16,970 Shares in United Therapeutics Corporation $UTHR Purchased by Nykredit A S

September 6 at 5:03 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,687,870.00 in Stock

September 6 at 4:07 AM | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,000,849.00 in Stock

September 6 at 4:07 AM | americanbankingnews.com

Odyssean LLC Purchases 2,358 Shares of United Therapeutics Corporation $UTHR

September 5 at 4:55 AM | marketbeat.com

United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?

September 4 at 12:36 PM | zacks.com

United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares

September 4 at 6:07 AM | insidertrades.com

United Therapeutics (NASDAQ:UTHR) Stock Price Down 4.7% on Insider Selling

September 4 at 1:21 AM | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

September 3, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

September 3, 2026 | marketbeat.com

FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis

September 3, 2026 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and Medtronic (MDT)

September 3, 2026 | theglobeandmail.com

FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis

September 3, 2026 | finance.yahoo.com

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

September 2, 2026 | rutlandherald.comR

United Therapeutics Announces FDA Acceptance Of SNDA For Nebulized Tyvaso In IPF

September 2, 2026 | rttnews.com

United Therapeutics bid to expand nebulized Tyvaso label gets FDA review

September 2, 2026 | msn.com

United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone

September 2, 2026 | quiverquant.comQ

United Therapeutics (NASDAQ:UTHR) Shares Down 4.7% on Insider Selling

September 2, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $118.21 Million Position in United Therapeutics Corporation $UTHR

September 2, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

September 2, 2026 | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,855,355.00 in Stock

September 1, 2026 | marketbeat.com

Two Sigma Securities LLC Purchases 2,216 Shares of United Therapeutics Corporation $UTHR

September 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ERAS, RVMD, GMAB, and UTHR Company Descriptions

Erasca NASDAQ:ERAS

$16.19 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Genmab A/S NASDAQ:GMAB

$33.60 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Revolution Medicines NASDAQ:RVMD

$210.02 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

United Therapeutics NASDAQ:UTHR

$487.61 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ERAS, RVMD, GMAB, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ERAS, RVMD, GMAB, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ERAS, RVMD, GMAB, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ERAS, RVMD, GMAB, and UTHR Company Descriptions

Erasca NASDAQ:ERAS

Genmab A/S NASDAQ:GMAB

Revolution Medicines NASDAQ:RVMD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ERAS, RVMD, GMAB, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ERAS, RVMD, GMAB, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ERAS, RVMD, GMAB, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ERAS, RVMD, GMAB, and UTHR Company Descriptions

Erasca NASDAQ:ERAS

Genmab A/S NASDAQ:GMAB

Revolution Medicines NASDAQ:RVMD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools